echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: HPV vaccine is effective in preventing cervical cancer.

    NEJM: HPV vaccine is effective in preventing cervical cancer.

    • Last Update: 2020-10-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    March 20, 2020 /--- According to a large study published in the journal New England Journal of Medicine by researchers at the Karolinska Institute in Sweden, women who have been vaccinated against HPV have a significantly lower risk of developing cervical cancer, the most significant positive effect for young women.
    "This is the first time that HPV vaccination has been shown at the population level that HPV vaccination can not only prevent cell mutations that can lead to cervical cancer, but also prevent the actual occurrence of indulging cervical cancer."
    's something we've long suspected.
    (Photo: www.pixabay.com) HPV (human papillomavirus) is a type of virus that usually causes warts and various types of cancer, including cervical cancer, which kills more than 250,000 women worldwide each year.
    more than 100 countries have implemented national vaccination programmes for HPV.
    previous studies have shown that the HPV vaccine can prevent HPV infection, warts and pre-cancer cervical lesions that can develop into cervical cancer.
    , however, there is still a lack of large population-based research.
    study, researchers tracked about 1.7 million women between the ages of 10 and 30 over 11 years.
    , more than 500,000 people have been vaccinated against HPV, most of whom have been diagnosed before the age of 17.
    Compared to 538 unvaccinated women, an analysis by 47 and 94 female researchers per 100,000 people showed that HPV vaccination was associated with a significant reduction in the risk of cervical cancer, and that girls who were vaccinated before the age of 17 had an 88 percent lower risk of cervical cancer.
    the study showed that women who were vaccinated between the ages of 17 and 30 had a half lower risk of cervical cancer than unvaccinated women.
    "Girls who are vaccinated at a young age seem to be given more protection, probably because they are less likely to be infected with HPV, and given that HPV vaccination has no therapeutic effect on past infections," said Pär Sparén, a researcher at the university.
    overall, our study shows that HPV vaccination can significantly reduce the risk of cervical cancer, especially when completed early," PärSparén said.
    "our data strongly support the continuation of HPV vaccinations for children and adolescents through national vaccination programmes.
    Bioon.com Source: HPV vaccine effective against cervical cancer Source: "HPV Vaccine and Risk of Invasive Cervical Cancer," Jiayao Lei, Alexander Ploner, Miriam Elfström, Jiangrong Wang, Adam Roth, Fang Fang, Karin Sundström, Joakim Dillner, Pär Sparén, New England Journal of Medicine (2020). DOI: 10.1056/NEJMoa1917338.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.